Modality
Peptide
MOA
BTKi
Target
Tau
Pathway
PD-1/PD-L1
NSCLCUrothelial CaIPF
Development Pipeline
Preclinical
~Apr 2014
→ ~Jul 2015
Phase 1
~Oct 2015
→ ~Jan 2017
Phase 2
~Apr 2017
→ ~Jul 2018
Phase 3
Oct 2018
→ Jan 2029
Phase 3Current
NCT05678931
197 pts·NSCLC
2018-10→2029-01·Active
NCT03564297
938 pts·IPF
2020-02→2027-02·Active
1,135 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-02-1511mo awayPh3 Readout· IPF
2029-01-102.8y awayPh3 Readout· NSCLC
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P3
Active
P3
Active
Catalysts
Ph3 Readout
2027-02-15 · 11mo away
IPF
Ph3 Readout
2029-01-10 · 2.8y away
NSCLC
Active|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Lisorapivir | Takeda | Preclinical | WRN |